GoodRx saw a positive market reaction to its first-quarter results, with management attributing performance to robust growth in its Pharma Direct segment and steady engagement in subscriptions. CEO Wendy Barnes emphasized that the company’s investments in manufacturer-sponsored pricing programs and weight loss subscriptions were key drivers, noting that Pharma Direct revenue grew 82% year over year. Barnes highlighted GoodRx’s role in supporting major GLP-1 therapy launches, including the Wegovy Pill, and pointed to the expanding influence of its digital access platform in connecting patients and manufacturers. The company also reported stable monthly active consumers in its prescription transactions business, reflecting ongoing engagement despite broader industry shifts.
Is now the time to buy GDRX? Find out in our full research report (it’s free for active Edge members).
GoodRx (GDRX) Q1 CY2026 Highlights:
- Revenue: $194 million vs analyst estimates of $184.6 million (4.4% year-on-year decline, 5.1% beat)
- Adjusted EPS: $0.07 vs analyst estimates of $0.07 (in line)
- Adjusted EBITDA: $58.27 million vs analyst estimates of $56.14 million (30% margin, 3.8% beat)
- The company lifted its revenue guidance for the full year to $775 million at the midpoint from $765 million, a 1.3% increase
- EBITDA guidance for the full year is $235 million at the midpoint, in line with analyst expectations
- Operating Margin: 7.2%, down from 11.5% in the same quarter last year
- Market Capitalization: $911 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From GoodRx’s Q1 Earnings Call
- Michael Cherny (Leerink Partners) asked about the sustainability of Pharma Direct and subscription growth. CFO Christopher McGinnis explained that prescription transaction revenue is expected to remain pressured, but Pharma Direct and subscriptions provide a more durable revenue stream.
- Payton Engdahl (Truist) questioned the impact of the Surescripts partnership. CEO Wendy Barnes and McGinnis both stated that it had no material impact on results or guidance this quarter.
- John Ransom (Raymond James) probed on core Rx Marketplace stabilization and the effect of retail pharmacy consolidation. Barnes said GoodRx works with all major retailers and is less sensitive to shifts as a result of diversified partnerships.
- Charles Rhyee (TD Cowen) inquired about total prescriptions processed and whether growth in Pharma Direct was cannibalizing core transactions. McGinnis acknowledged some cannibalization is preferred, as Pharma Direct revenue is more durable long-term.
- Maxi Ma (Deutsche Bank) asked how GoodRx differentiates its GLP-1 offering amid increasing competition. Barnes emphasized high brand recognition, prescriber engagement, and a broad retail network as key advantages.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) sustained momentum in Pharma Direct, particularly as more GLP-1 therapies and manufacturer partnerships launch, (2) further adoption and scaling of condition-specific subscription programs, and (3) stabilization of engagement metrics in the core prescription transactions business. Tracking the impact of employer partnerships and digital pharmacy expansion will also be key to assessing GoodRx’s long-term growth trajectory.
GoodRx currently trades at $2.71, up from $2.57 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
